Royalty Report: Drugs, Disease, Therapeutic – Collection: 203304

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Parkinsons Disease
  • Personal Care Products
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 203304

License Grant
The Israeli Licensor grants a non-exclusive, worldwide license to all Intellectual Property Rights solely for the manufacture, development, formulation, use, sale, offer for sale, and importation of finished pharmaceutical products that contain the compound modafinil, including, without limitation, its salts, esters, enantiomers, isomers and polymorphs, including without limitation, any aspect of such rights which purport to cover or relate to PROVIGIL®, SPARLON® and/or NUVIGIL®]
License Property
Modafinil Product shall mean all finished pharmaceutical products that contain the compound modafinil, including, without limitation, its salts, esters, enantiomers, isomers and polymorphs, including without limitation, PROVIGIL®, SPARLON® and NUVIGIL®, sold by Licensee, its Affiliates, distributors and resellers.
Field of Use
This agreement is for the pharmaceutical industry, with specific applications for attention-deficit/hyperactivity disorder ADHD in children and adolescents, excessive sleepiness and Parkinsons Disease.

IPSCIO Record ID: 220120

License Grant
Licensor grants to the Licensee of Israel the right to use certain clinical and safety data codeveloped by Licensor in connection with studies of CEP-1347 for the treatment of Parkinsons Disease.

Licensor grants the non-exclusive right under the Listed Patents to manufacture, use, market and sell Generic Modafinil Product in the United States and other markets, including provision of modafinil API for Subject Modafinil Product or finished drug which has modafinil as an active ingredient.

License Property
Modafinil Product shall mean all finished pharmaceutical products that contain the compound modafinil, including, without limitation, its salts, esters, enantiomers, isomers and polymorphs, including without limitation, PROVIGIL®, SPARLON® and NUVIGIL®, sold by Cephalon, its Affiliates, distributors and resellers.
Field of Use
This agreement is for the pharmaceutical industry, with specific applications for attention-deficit/hyperactivity disorder ADHD in children and adolescents, excessive sleepiness and Parkinsons Disease.

IPSCIO Record ID: 29182

License Grant
The French Licensor granted an exclusive License for the Licensed Products and/or Combination Products from the Compound, and to use and sell Licensed Products throughout the Territory.
License Property
Licensed Product shall mean any pharmaceutical specialty whether sold by prescription, over-the-counter, or otherwise containing the Compound.

Compound shall mean modafinil and/or any other similar compound, isomer or salt thereof.  Licensor has discovered and developed an original compound, modafinil (INN) for which it owns patent rights in the U.S.A., such compound being useful in the field of the central nervous system.  Modafinil compound is the active drug substance contained in Provigil.

Field of Use
Provigil is approved for use by those suffering from excessive daytime sleepiness associated with narcolepsy.

IPSCIO Record ID: 233451

License Grant
Licensor grants a worldwide, exclusive license, with the right to sublicense, under the Licensors Rights, to Develop, make, have made, use, sell, offer for sale, have sold and import the Compound and Products in the Field, and otherwise to perform its obligations expressly set forth in this Agreement and the Co-Promotion Agreement.
License Property
The Compound means either (a) the Initial Compound or (b) any compound that is claimed in U.S. Patent No. 6,288,122 Bl and any hydrates, anhydrides, solvates, salts, esters or polymorphs thereof.

The initial compound means the compound ICA-17043 having the molecular structure set forth and any hydrates, anhydrides, solvates, salts, esters, isomers, prodrugs, metabolites or polymorphs thereof.

The Product means a pharmaceutical product that contains, incorporates or is comprised of the Compound, whether in development or approved by any Regulatory Authority, including all formulations, line extensions and modes of administration thereof.

The Licensor Patents means all Patents, other than CMCC Patents, Controlled by Licensor as of the Effective Date or during the Term, that, absent rights thereunder, would be infringed by the Development, Manufacture, formulation, use, distribution, importation, sale, or offer for sale of Compound or Product, including without limitation any such Patents claiming the composition of matter or the use of Compound or Product or any Improvements thereto.

Licensors know-how means all Information, except for CMCC Know-How, that Licensor Controls as of the Effective Date or during the Term.

Field of Use
The field means prevention and treatment of all human and animal diseases and disorders.  The licensed technology is for use of these compounds include treating sickle cell disease, preventing erythrocyte dehydration and inhibiting potassium flux.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.